Dr. Thomas Herzog on the Cautions of Interval Debulking Surgery in Ovarian Cancer

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

Mayra Shanley, PhD, discussed background and future directions for evaluating IL-21 natural killer cells for the treatment of glioblastoma.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Christopher Moertel, MD, discussed findings from the phase 2 ReNeu trial of mirdametinib in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

In an interview, Anil Parwani, MD, PhD, discussed how artificial intelligence can be used in medical education and training, as well as its role in personalized medicine.